Figure 2.
SVR12 rates. Error bars represent 95% CIs calculated by normal approximation to the binomial for the primary efficacy population and by Wilson score method for all others. The threshold of 63% (based on the historical telaprevir‐based SVR rate) to which the SVR12 rate for the primary efficacy population was compared is marked with a horizontal line in the first column. The primary efficacy population was composed of patients randomized to group A who received study drug and who were treatment‐naive without cirrhosis, were IFN‐eligible, and had HCV RNA ≥100,000 IU/mL. Abbreviations: DB, double‐blind; OL, open‐label.